Ipamorelin vs Sermorelin vs CJC-1295: Ghrelin Receptor Ligands and GHRH Analogs Compared

The ghrelin receptor, GHS-R1a, is a class A G protein-coupled receptor that couples principally through Gq, phospholipase C and intracellular calcium. Its endogenous ligand is acylated ghrelin. Synthetic ligands for this receptor are called growth hormone secretagogues, and the family includes the GHRPs, hexarelin and ipamorelin.

The GHRH receptor is a class B G protein-coupled receptor coupling through Gs and cAMP. Its endogenous ligand is the 44-residue growth hormone releasing hormone, and sermorelin, modified GRF(1-29) and CJC-1295 are all fragments or modified fragments of it.

The two receptors are co-expressed on the same secretory cell and converge on the same output through different second-messenger pathways, which is why a ghrelin receptor ligand and a GHRH analog are so often studied together. It is also why comparing them on potency is a category error. They are not competing for one receptor.

Ipamorelin is H-Aib-His-D-2-Nal-D-Phe-Lys-NH2, formula C38H49N9O5, molecular weight 711.86 Da. It contains one non-proteinogenic residue, alpha-aminoisobutyric acid, and two D-amino acids, D-2-naphthylalanine and D-phenylalanine, with a C-terminal amide. Nothing in it oxidizes readily and nothing deamidates.

Its defining property in the literature is selectivity. Earlier secretagogues in the same class also produced measurable ACTH, cortisol and prolactin responses in published work, which made it hard to attribute an observation to the ghrelin receptor rather than to the accompanying signaling. Ipamorelin largely does not, and it became the default tool compound for isolating ghrelin receptor signaling for that reason.

Hexarelin, H-His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 at 887.03 Da, is the useful contrast. It is more potent than ipamorelin at GHS-R1a but less selective, and it binds a second target, the scavenger receptor CD36, that ipamorelin does not. Choosing between them on potency alone is the common mistake; the right question is whether CD36 engagement is wanted or is a confound.

Sermorelin is GHRH(1-29) with a C-terminal amide, formula C149H246N44O42S, molecular weight 3357.9 Da. Residues 30 through 44 of the parent hormone are dispensable for receptor activation, and that structure-function finding is why every modified GHRH analog is built on the 1-29 frame.

Because it is unmodified, sermorelin is the least stable peptide in the category. DPP-4 cleaves between residues 2 and 3, the asparagine at position 8 rearranges, and the methionine at position 27 oxidizes. Certus labels reconstituted sermorelin for seven days at 2-8 °C and stocks it primarily as the minimally engineered comparator against which the modified analogs are judged.

Modified GRF(1-29), sold as CJC-1295 without DAC, keeps the 29-residue frame and makes four substitutions: D-Ala2, Gln8, Ala15 and Leu27. Each removes a specific degradation pathway of sermorelin: the D-alanine blocks DPP-4, the glutamine cannot rearrange the way asparagine does, and the leucine replaces the oxidizable methionine. Formula C152H252N44O42, molecular weight 3367.9 Da.

CJC-1295 with DAC adds a maleimide-bearing drug affinity complex to the C-terminal lysine that tethers the peptide to albumin in serum, raising the mass to 3647.2 Da and converting a pulsatile stimulus into a sustained one. The separate guide on the two CJC-1295 forms covers that difference in detail.

A five-residue synthesis has few steps and few opportunities for deletion. Where it fails is stereochemistry. The D-2-Nal and D-Phe residues in ipamorelin can epimerize to their L-forms during coupling, and the product is a diastereomer with exactly the same mass and formula. Mass spectrometry cannot see it. The only assay that catches it is chromatography against a qualified reference standard, ideally a chiral method, which is why the Certus certificate for ipamorelin carries a diastereomeric purity line with a specification of 99.0 % in addition to HPLC purity and mass.

A twenty-nine-residue synthesis has the opposite profile. Stereochemistry is rarely the problem; deletion sequences, truncations and incompletely removed side-chain protecting groups are. Those defects change the mass, so LC-MS against the theoretical value at a 1.0 Da tolerance is the decisive assay. Sermorelin and modified GRF(1-29) are only ten daltons apart, which is well within that tolerance's power to distinguish, so the mass alone tells you which of the two is in the vial.

Long peptides also aggregate. Both 29-mers should be swirled rather than shaken on reconstitution, and both carry tryptophans that photo-oxidize, so reconstituted solutions are kept out of light.

Ipamorelin: HPLC purity against 99.0 %, LC-MS observed mass within 1.0 Da of 711.86, diastereomeric purity by chiral reversed-phase HPLC against a reference standard, net peptide content, endotoxin and sterility. The chiral line is the one that distinguishes a certificate written for this compound from a generic template.

Sermorelin: HPLC purity against 98.0 %, mass within 1.0 Da of 3357.9, and attention to the oxidation product at +16 Da from the methionine at position 27, which appears as a separate earlier-eluting peak on reversed phase. An aged or badly stored lot shows it.

Modified GRF(1-29): HPLC purity against 99.0 %, mass within 1.0 Da of 3367.9, and a statement of the modification set, since the four substitutions are what distinguish it from sermorelin and only one of them, Leu27 for Met27, changes the composition enough to show in the formula.

The classic experiment in this category runs a ghrelin receptor ligand and a GHRH analog separately and together, because the two receptors converge on one secretory output through Gq and Gs respectively and the interaction between the pathways is itself the question. Ipamorelin plus modified GRF(1-29) is the standard pairing because both are selective and both are stable enough to give a clean comparison. Sermorelin substitutes for the GHRH arm when the point is to compare an engineered analog with the native fragment, and hexarelin substitutes for the ghrelin arm when CD36 is part of the question.